SCHEMBL25927899

SCHEMBL25927899

CCCCNN1C(=O)CSc2ccc(C(=O)Nc3ccc(S(=O)(=O)N4CCCCC4)cc3)cc21

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ KMT2A Q03164 4/20 0.54
▸ KDM4E B2RXH2 1/20 0.54
▸ TAAR1 Q96RJ0 1/20 0.54
▸ POLB P06746 3/20 0.52
▸ TP53 P04637 1/20 0.52
▸ ALDH1A1 P00352 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ USP2 O75604 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ TSHR P16473 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25922300 0.88 CTDSP1 (0.61) CTDSP1KMT2AKDM4ETAAR1POLB
SCHEMBL25922340 0.86 CTDSP1 (0.64) CTDSP1KMT2AKDM4EPOLBALDH1A1
SCHEMBL24125225 0.84 ALDH1A1 (0.51) CTDSP1KMT2AKDM4ETP53ALDH1A1
SCHEMBL30270587 0.83 CYP1A2 (0.58) CTDSP1KMT2AKDM4EPOLBTP53
SCHEMBL25921866 0.83 CYP1A2 (0.58) CTDSP1KMT2AKDM4EPOLBTP53
SCHEMBL25922344 0.82 CYP1A2 (0.56) CTDSP1KMT2AKDM4EPOLBTP53
SCHEMBL25922279 0.80 CTDSP1 (0.58) CTDSP1KMT2AKDM4EPOLBTP53
SCHEMBL25922275 0.79 TP53 (0.59) CTDSP1KMT2AKDM4EPOLBTP53
SCHEMBL24125231 0.76 ALDH1A1 (0.61) POLBTP53ALDH1A1MAPTUSP2
SCHEMBL25930932 0.75 MAPT (0.52) CTDSP1KMT2AKDM4EPOLBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 CTDSP1 2570/4885KMT2A 578/4885KDM4E 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback